-
Ewopharma AG Announces Exclusive Distribution Agreement for Cardiovascular Solutions in Bulgaria
Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and Blue Medical’s drug-coated balloon (DCB) technologies in Bulgaria. The agreement includes two key categories of interventional cardiovascular solutions: Drug-Eluting Stents – The DES category includes biodegradable polymer and polymer-free drug-eluting stents incorporating proprietary coatings and drug formulations to reduce restenosis and improve safety. Drug-Coated Balloons – DCB treatment is based on a leave-nothing-behind concept, which ensures homogenous and immediate drug delivery to the vessel wall without the use of a polymer thus eliminating the presence of residual foreign material in the vessel. “We are proud to expand our portfolio with Translumina’s cardiovascular solutions…
-
AllergyCare AG Becomes Part Of Ewopharma Group
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of AllergyCare AG, a Swiss distribution company of pharmaceutical and consumer health products with a focus on the prevention and treatment of allergies. As part of a succession solution, the Ewopharma Group was able to acquire AllergyCare AG retroactively from 1st January 2024. Ewopharma and AllergyCare AG enjoyed several specific points of contact through the same brand they represent. For the last decades, Ewopharma Group has successfully grown its business and continued its geographic expansion. The acquisition opens new expertise for Ewopharma to explore the Swiss home market, this…
-
Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer therapies. Under the agreement, Ewopharma will gain the commercial rights for sugemalimab in Switzerland and 18 Central Eastern European countries (CEE). These include EU member countries Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia, as well as non- EU countries Albania, Bosnia & Herzegovina, Kosovo, North Macedonia, Moldova, Montenegro, Serbia. The partnership will maximize the value of sugemalimab (anti-PD-L1 monoclonal antibody) in Central Eastern Europe and Switzerland. CStone will receive up to $51.3 million in…
-
Neomed s.r.o. becomes part of Ewopharma Group
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, medical devices, and cosmetics. As part of a succession solution, the Ewopharma Group was able to acquire Neomed s.r.o. as of 1 June 2023. In the past, Ewopharma and Neomed enjoyed several specific, successful collaborations in the region. Over the past years, Ewopharma has successfully grown the business and continued to expand geographically. The acquisition opens new expertise for Ewopharma, this with Neomed’s existing staff and partnerships. Mr. Alain Staub, CEO of the Ewopharma Group, commented “This is an important…
